Phase I trial of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG), a heat shock protein inhibitor, administered twice weekly in patients with advanced malignancies
European Journal of Cancer2009Vol. 46(2), pp. 340–347
Citations Over TimeTop 10% of 2009 papers
Shivaani Kummar, Martin Gutierrez, Erin R. Gardner, Xiaohong Chen, William D. Figg, Maria Zajac‐Kaye, Min Chen, Seth M. Steinberg, Christine Muir, Mary Ann Yancey, Yvonne Horneffer, Lamin Juwara, Giovanni Melillo, S. Percy Ivy, Maria J. Merino, Len Neckers, Patricia S. Steeg, Barbara A. Conley, Giuseppe Giaccone, James H. Doroshow, Anthony J. Murgo
Related Papers
- → Drug tolerability: How much ambiguity can be tolerated? A systematic review of the assessment of tolerability in clinical studies(2021)45 cited
- → Safety and Tolerability of Gabapentin as Adjunctive Therapy in a Large, Multicenter Study(1999)81 cited
- → Real-World Evaluation of the Tolerability to Onabotulinum Toxin A: The RETO Study(2022)4 cited
- → Tolerability of combined treatment with lithium and fluoxetine(1994)26 cited
- Tolerability of topical antimicrobials in treatment of acne vulgaris.(2014)